| Metric | Q1 FY27 | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue from operations | 653.2 | 629.2 | 603.0 |
| Other income | 44.8 | 40.7 | 67.2 |
| Total income | 698.0 | 670.0 | 670.2 |
| Profit before exceptional items & tax | 276.7 | 259.8 | 259.5 |
| Exceptional items | 0.0 | 9.0 | 0.0 |
| Profit before tax | 276.7 | 268.8 | 259.5 |
| Net profit | 204.5 | 199.8 | 191.8 |
| Operating margin | 39.6% | 40.1% | 38.7% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +6.60% |
|---|---|
| Net profit, quarter on quarter | +2.40% |
| Revenue, year on year | +8.30% |
| Operating profit, year on year | +28.20% |
| Operating profit, quarter on quarter | +0.40% |
BSE results filing, NSE: PFIZER. Figures extracted from the filing.
Pfizer Ltd: key numbers
- Share price
- ₹3,810.00
- Market cap
- ₹17,430 Cr
- Revenue (annual)
- ₹2,520 Cr
- Net profit (annual)
- ₹722.4 Cr
- P/E (TTM)
- 23.7×Sector 47.4×
- Promoter holding
- 63.92%+0.00% QoQ
- FII holding
- 1.65%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Pfizer Ltd
All →Pfizer Management Change
Pfizer Limited announced the resignation of Mr. Sharad Goswami, Senior Director – Policy & Public Affairs, effective from the close of business on September 25, 2026.
Pfizer Board Meeting Outcome
Pfizer Board approved discontinuation of Minipress XL effective September 7, 2026. The company will receive ₹131.38 Crore lump-sum payment from Pfizer Inc., USA.
- Value
- ₹131.4 Cr
Pfizer Annual General Meeting
Pfizer Limited held its 75th Annual General Meeting on July 28, 2026. The meeting covered the adoption of financial statements, dividend declaration, and auditor remuneration ratification.
Pfizer Management Change
Mr. Amit Agarwal has resigned as the Executive Director – Finance & Chief Financial Officer and Director of Pfizer Limited, effective October 8, 2026.
Pfizer Board Meeting Date
Pfizer Limited has scheduled a board meeting for July 28, 2026, to consider and approve the unaudited standalone financial results for the quarter ended June 2026.
Pfizer Price Movement Clarification
Pfizer clarified that Premarin Vaginal Cream's temporary discontinuation due to supply constraints has no material impact. The product contributes less than 1% of total revenue.